Bezisterim can manage inflammation and enhance energy transfer (insulin sensitivity) in the brain. Learn how it is in trials to improve memory and thinking in Alzheimer’s. (Video+Article)
A well-known driver of Alzheimer’s is inflammation. Inflammation is often caused by too much methylation (hypermethalation). In clinical trials, the new drug Bezisterim (also known as NE3107) helped keep methylation in balance, measurably reducing inflammation and the cognitive decline it causes.
These results were seen in the analysis of data generated from BioVie’s Phase 3 trial in Alzheimer’s disease (AD). The DNA methylation dataset assessed the extent of DNA methylation on roughly 965,000 individual sites where methyl groups can be attached to the patients’ DNA.
“We all age and get older – nothing can change that. But these data provide evidence that bezisterim may have the potential to help keep people healthier for a longer time as we age,” said Cuong Do, BioVie’s President and CEO. “BioVie believes that DNA methylation may …
![Colorado farm worker tests positive for H5N1 bird flu, CDC says NBC Connecticut [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/07/mp_353459_0_AP24185672170337jpg.jpg)
![A big improvement to Workable: The new pipeline view [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/07/mp_353541_0_CandidateBrowserFeaturedimage1200x6284jpg.jpg)
![Bachelor of Theology (BTheol) | University of Otago [Video]](https://cancerrecoverygiving.com/wp-content/uploads/2024/07/mp_350496_0_studyspyelephantpng.png)
